Treatment of Hypertensive Patients with renal Diseases

I.O. Dudar

Abstract


The review is devoted to the issues of treatment of hypertensive patients with acute renal disorders and chronic renal disease with proteinuria and without it. It was emphasized that the treatment of hypertensive patients with renal diseases is prescribed after detailing the type of kidney disorder, presence of proteinuria, edema syndrome, glomerular filtration rate. Arterial hypertension with concomitant acute glomerulus lesion and edemas requires dewatering with diuretic agents and dialysis, if necessary. In patients with chronic renal disease and proteinuria the inhibitors of angiotensin-converting enzyme and antagonists of angiotensin receptors are the agents of the first line. Olmesartanum medoxomilum was proved to have more expressed renoprotective effects among all antagonisits of angiotensin receptors.


Keywords


arterial hypertension; chronic renal disease; acute kidney lesions; treatment

References


Дудар І.О., Паламар Б.І., Красюк Е.К., Петрова А.С. Поширеність ХХН VД стадії у світі та в Україні // Здоров’я України. — 2015. — № 3–4. — C. 10-12.

Bakris G.L., Ritz E. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented // Kidney Int. — 2009. — № 75. — C. 449.

Catapano F., Chiodini P., De Nicola L. et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression // Am. J. Kidney Dis. — 2008. — № 52. — C. 475.

Rodríguez-Iturbe B., Colic D., Parra G., Gutkowska J. Atrial natriuretic factor in the acute nephritic and nephrotic syndromes // Kidney Int. — 1990. — № 38. — C. 512.

Valentin J.P., Qiu C., Muldowney W.P. et al. Cellular basis for blunted volume expansion natriuresis in experimental nephrotic syndrome // J. Clin. Invest. — 1992. — № 90. — C. 1302.

Buerkert J., Martin D.R., Trigg D., Simon E.E. Sodium handling by deep nephrons and the terminal collecting duct in glomerulonephritis // Kidney Int. — 1991. — № 39. — C. 850.

Zolty E., Ibnou-Zekri N., Izui S. et al. Glomerulonephritis and sodium retention: enhancement of Na+/K+-ATPase activity in the collecting duct is shared by rats with puromycin induced nephrotic syndrome and mice with spontaneous lupus-like glomerulonephritis // Nephrol. Dial Transplant. — 1999. — № 14. — C. 2192.

Whaley-Connell A.T., Sowers J.R., Stevens L.A. et al. CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999–2004 // Am. J. Kidney Dis. — 2008. — № 51. — C. S13.

Buckalew V.M. Jr, Berg R.L., Wang S.R. et al. Prevalence of hypertension in 1,795 subjects with chronic renal disease: the modification of diet in renal disease study baseline cohort. Modification of Diet in Renal Disease Study Group // Am. J. Kidney Dis. — 1996. — № 28. — C. 811.

Neumann J., Ligtenberg G., Klein I.I. et al. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment // Kidney Int. — 2004. — № 65. — C. 1568.

Raine A.E., Bedford L., Simpson A.W. et al. Hyperparathyroidism, platelet intracellular free calcium and hypertension in chronic renal failure // Kidney Int. — 1993. — № 43. — C. 700.

Passauer J., Pistrosch F., Büssemaker E. et al. Reduced agonist-induced endothelium-dependent vasodilation in uremia is attributable to an impairment of vascular nitric oxide // J. Am. Soc. Nephrol. — 2005. — № 16. — C. 959.

London G., Guerin A., Pannier B. et al. Increased systolic pressure in chronic uremia. Role of arterial wave reflections // Hypertension. — 1992. — № 20. — C. 10.

Portaluppi F., Montanari L., Massari M. et al. Loss of nocturnal decline of blood pressure in hypertension due to chronic renal failure // Am. J. Hypertens. — 1991. — № 4. — C. 20.

Parra G., Rodríguez-Iturbe B., Colina-Chourio J., García R. Short-term treatment with captopril in hypertension due to acute glomerulonephritis // Clin. Nephrol. — 1988. — № 29. — C. 58.

Hiroki Ikeda. Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes // Deabetes Research and Clinical Practice. — 2009. — 83. — P. 117-118.

Daikuhara Н., Fukunaga К., Ohshima Т. Difference in the effects of switching from Candesartan to Olmesartan or Telmisartan to Olmesartan in hypertensive patients with type 2 diabetes: the COTO study // Drug Design, Development and Therapy. — 2014. — 8. — P. 219-226.

Takashi Ono, Toru Sanai, Yoshito Miyahara, Ritsuya Noda. Olmesartan is More Effective Than Other Angiotensin Receptor Antagonists in Reducing Proteinuria in Patients With Chronic Kidney Disease Other Than Diabetic Nephropathy // Current Therapeutic Research. — 2013. — 74. — P. 62-67.

Miura S., Fujino M., Hanzawa H. et al. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor // J. Biol. Chem. — 2006. — 281. — 19288-19295.

Miura S., Kiya Y., Kanazawa T. et al. Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabili-zing the inactive state // Mol. Endocrinol. — 2008. — 22. — 139-146.

Furuhashi M., Moniwa N., Ishimura S., Mita T. et al. Possible increase in urinary angiotensinconverting enzyme 2 by olmesartan, an angiotensin II receptor blocker, in hypertensive patients // European Heart Journal. — 2014. — 35 (Abstract Supplement). — 66.

Minutolo R., Agarwal R., Borrelli S. et al. Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease // Arch. Intern. Med. — 2011. — № 171. — C. 1090.

Agarwal R., Andersen M.J. Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease // Kidney Int. — 2006. — № 69. — C. 1175.

Slagman M.C., Waanders F., Hemmelder M.H. et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial // BMJ. — 2011. — № 343. — C. 4366.

Reubi F.C., Cottier P.T. Effects of reduced glomerular filtration rate on responsiveness to chlorothiazide and mercurial diuretics // Circulation. — 1961. — 23. — 200.

Wollam G.L., Tarazi R.C., Bravo E.L., Dustan H.P. Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia // Am. J. Med. — 1982. — № 72. — C. 929.

Sica D.A. Chlorthalidone: has it always been the best thiazide-type diuretic? // Hypertension. — 2006. — № 47. — C. 321.

Khosla N., Kalaitzidis R., Bakris G.L. The kidney, hypertension, and remaining challenges // Med. Clin. North Am. — 2009. — № 93. — C. 697.

Buter H., Hemmelder M.H., Navis G. et al. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide // Nephrol. Dial. Transplant. — 1998. — № 13. — C. 1682.

Wilmer W.A., Rovin B.H., Hebert C.J. et al. Management of glomerular proteinuria: a commentary // J. Am. Soc. Nephrol. — 2003. — № 14. — C. 3217.

Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR< 45 mL/min) // Nephrol. Dial. Transplant. — 2015. —

(suppl. 2). — ii1-ii142. doi: 10.1093/ndt/gfv100.

Bakris G.L., Weir M.R., Secic M. et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression // Kidney Int. — 2004. — № 65. — C. 1991.

Kent D.M., Jafar T.H., Hayward R.A. et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease // J. Am. Soc. Nephrol. — 2007. — № 18. — C. 1959.

Menne J., Ritz Е., Ruilope L.M., Chatzikyrkou С., Viberti G., Haller Н. The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) Observational Follow-Up Study: Benefits of RAS Blockade With Olmesartan Treatment Are Sustained After Study Discontinuation // Journal of the American Heart Association. — Downloaded from http://jaha.ahajournals.org/ by guest on November 28, 2014.

Khosla N., Kalaitzidis R., Bakris G.L. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade // Am. J. Nephrol. — 2009. — № 30. — C. 418.

Minutolo R., Gabbai F.B., Borrelli S. et al. Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial // Am. J. Kidney Dis. — 2007. — № 50. — C. 908.

Hermida R.C., Ayala D.E., Mojón A., Fernández J.R. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD // J. Am. Soc. Nephrol. — 2011. — № 22. — C. 2313.

Kentaro Ushijima, Hajime Nakashima, Tsuyoshi Shiga еt al. Different chronotherapeutic effects of valsartan and olmesartan in non-dipper hypertensive patients during valsartan treatment at morning // Journal of Pharmacological Sciences. — 2015. — 127. — P. 62-68

Blood Pressure Lowering Treatment Trialists’ Collaboration, Turnbull F., Neal B. et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials // BMJ. — 2008. — № 338. — C. 1121.

Heerspink H.J., Ninomiya T., Zoungas S. et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials // Lancet. — 2009. — № 373. — C. 1009.




DOI: https://doi.org/10.22141/2224-1485.4.48.2016.76990

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru